Rls Review

March 2026

Rls Review (March 2026)

RLS owns and operates 31 radiopharmacies across 18 states, offering an extensive portfolio of molecular imaging products.

$93MRevenue

462Employees

14%Growth

$93M

Revenue

462

Employees

14%

Growth

Estimated Revenue

$93M

Total Employees

462

Employee Growth

14%

Industry

About

RLS owns and operates 31 radiopharmacies across 18 states, offering an extensive portfolio of molecular imaging products.

Global Rank

N/A

Rls's estimated revenue is $93M.

RLS owns and operates 31 radiopharmacies across 18 states, offering an extensive portfolio of molecular imaging products.

Company	Revenue	Employees	Growth	Funding
Imaging Endpoints	$53.7M	267	16.3%	N/A
Southern Scripts	$53.1M	264	21.1%	N/A
Alfasigma USA	$69.1M	344	26.2%	N/A
US WorldMeds	$22.1M	110	-9.9%	N/A
PharmaCord	$151.8M	755	11.4%	N/A
KCAS Bioanalytical and Biomarker Services	$63.9M	318	13.4%	N/A
BioTek reMEDys	$29.9M	149	12.8%	N/A
Endocyte	$1.7M	17	-5.9%	$114.3M
Envision Communications	$6.8M	34	-6.7%	N/A
Peachtree Bioresearch Solutions	$12.5M	62	-8.9%	N/A